- InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties
- The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities
- Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will be responsible for developing, manufacturing, and commercializing the candidates
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Pharma Boardroom
The post InveniAI Collaborates with Shionogi on AI-Based Drug Discovery first appeared on PharmaShots.